Category - News

Markets

Alliance Global starts T2 Biosystems at buy; PT $5.00

Alliance Global Partners launched coverage of T2 Biosystems (NASDAQ:TTOO) with a “buy” rating and price target of $5.00. The stock closed at $2.62 on May 15.

May 16, 2019

Developments

Ceapro receives site license from Health Canada

Ceapro’s (TSXV:CZO) two bioprocessing plants in Alberta received a site license from the Health Canada Natural and Non-Prescription Health Products Directorate, which enables the company to fabricate, package, label...

May 15, 2019

Developments

Principia Biopharma doses first patient in Phase 2b MS trial

Principia Biopharma (NASDAQ:PRNB) has dosed the first patient in its Phase 2b clinical trial of SAR442168 in patients with relapsing multiple sclerosis (MS). Neuroinflammation and an increase in the number of B cells in...

May 15, 2019

Markets

BTIG cuts electroCore to neutral

BTIG downgraded electroCore (NASDAQ:ECOR) to a “neutral” rating following the company’s release of its first quarter 2019 results. The stock closed at $5.33 on May 14.

May 15, 2019

Developments

Athersys gets FDA fast track designation for acute respiratory distress syndrome

Athersys’ (NASDAQ:ATHX) MultiStem cell therapy for the treatment of acute respiratory distress syndrome (ARDS) has received FDA fast track designation. ARDS is a widespread inflammation of the lungs that can be...

May 15, 2019

Developments

MeiraGTx reports positive topline data from Phase 1/2 retinal dystrophy trial

MeiraGTx (NASDAQ:MGTX) reported that AAV-RPE65, its investigational gene therapy for the treatment of retinal dystrophy, met the primary endpoint of safety and tolerability in a Phase 1/2 study, as well as demonstrated...

May 14, 2019

Developments

Homology’s PKU gene therapy gets FDA fast track designation

Homology Medicines’ (NASDAQ:FIXX) received FDA fast track designation for HMI-102, a gene therapy for the treatment of adults with phenylketonuria (PKU), a rare genetic disease affecting metabolism. Individuals with PKU...

May 14, 2019

Developments

Cyclerion completes enrollment for Phase 2 studies of praliciguat

Cyclerion Therapeutics (NASDAQ:CYCN) has completed enrollment for Phase 2 studies testing praliciguat in diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF). Praliciguat stimulates soluble...

May 14, 2019

Executive Moves

Neptune Wellness names Martin Landry as chief of corporate development and strategy

Neptune Wellness Solutions (NASDAQ:NEPT; TSX:NEPT) appointed Martin Landry to the new position of chief of corporate development and strategy, effective May 27.

May 14, 2019

Markets

BTIG ups TransEnterix to buy; PT $3

BTIG upgraded TransEnterix (NASDAQ:TRXC) to “buy” from “neutral” with a price target of $3, saying it sees more upside potential than downside risk at current share prices.

May 14, 2019

Category - News

Alliance Global starts T2 Biosystems at buy; PT $5.00

Ceapro receives site license from Health Canada

Principia Biopharma doses first patient in Phase 2b MS trial

BTIG cuts electroCore to neutral

Athersys gets FDA fast track designation for acute respiratory distress syndrome

MeiraGTx reports positive topline data from Phase 1/2 retinal dystrophy trial

Homology’s PKU gene therapy gets FDA fast track designation

Cyclerion completes enrollment for Phase 2 studies of praliciguat

Neptune Wellness names Martin Landry as chief of corporate development and strategy

BTIG ups TransEnterix to buy; PT $3

General

More